Cargando…
Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643148/ https://www.ncbi.nlm.nih.gov/pubmed/33149116 http://dx.doi.org/10.1038/s41408-020-00374-3 |
| _version_ | 1783606221013516288 |
|---|---|
| author | Thiant, S. Moutuou, M. M. Laflamme, P. Boumedine, R. Sidi Leboeuf, D. M. Busque, L. Roy, J. Guimond, M. |
| author_facet | Thiant, S. Moutuou, M. M. Laflamme, P. Boumedine, R. Sidi Leboeuf, D. M. Busque, L. Roy, J. Guimond, M. |
| author_sort | Thiant, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7643148 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76431482020-11-10 Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients Thiant, S. Moutuou, M. M. Laflamme, P. Boumedine, R. Sidi Leboeuf, D. M. Busque, L. Roy, J. Guimond, M. Blood Cancer J Correction Nature Publishing Group UK 2020-11-04 /pmc/articles/PMC7643148/ /pubmed/33149116 http://dx.doi.org/10.1038/s41408-020-00374-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correction Thiant, S. Moutuou, M. M. Laflamme, P. Boumedine, R. Sidi Leboeuf, D. M. Busque, L. Roy, J. Guimond, M. Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients |
| title | Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients |
| title_full | Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients |
| title_fullStr | Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients |
| title_full_unstemmed | Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients |
| title_short | Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients |
| title_sort | correction: imatinib mesylate inhibits stat5 phosphorylation in response to il-7 and promotes t cell lymphopenia in chronic myelogenous leukemia patients |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643148/ https://www.ncbi.nlm.nih.gov/pubmed/33149116 http://dx.doi.org/10.1038/s41408-020-00374-3 |
| work_keys_str_mv | AT thiants correctionimatinibmesylateinhibitsstat5phosphorylationinresponsetoil7andpromotestcelllymphopeniainchronicmyelogenousleukemiapatients AT moutuoumm correctionimatinibmesylateinhibitsstat5phosphorylationinresponsetoil7andpromotestcelllymphopeniainchronicmyelogenousleukemiapatients AT laflammep correctionimatinibmesylateinhibitsstat5phosphorylationinresponsetoil7andpromotestcelllymphopeniainchronicmyelogenousleukemiapatients AT boumedinersidi correctionimatinibmesylateinhibitsstat5phosphorylationinresponsetoil7andpromotestcelllymphopeniainchronicmyelogenousleukemiapatients AT leboeufdm correctionimatinibmesylateinhibitsstat5phosphorylationinresponsetoil7andpromotestcelllymphopeniainchronicmyelogenousleukemiapatients AT busquel correctionimatinibmesylateinhibitsstat5phosphorylationinresponsetoil7andpromotestcelllymphopeniainchronicmyelogenousleukemiapatients AT royj correctionimatinibmesylateinhibitsstat5phosphorylationinresponsetoil7andpromotestcelllymphopeniainchronicmyelogenousleukemiapatients AT guimondm correctionimatinibmesylateinhibitsstat5phosphorylationinresponsetoil7andpromotestcelllymphopeniainchronicmyelogenousleukemiapatients |